David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology,
Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen University of California, Los Angeles School of Medicine
Los Angeles, CA
Michele Rubin, APN, CNS, CGRN
IBD Clinical Nurse Specialist
UCM APN Chair
CCFA Nurse Initiatives Committee
University of Chicago Medicine
Mobile + Online on RealCME
This activity simulates a quality improvement initiative to illuminate best practices in the immunization of patients with IBD.
Gastroenterologists, gastroenterology fellows, gastroenterology NPs/PAs, gastroenterology nurses, and other healthcare providers who manage patients with IBD, including primary care/internal medicine clinicians
Upon completion of this educational activity, the participant should be able to:
- Discuss the 2017 American College of Gastroenterology guidelines for immunizing patients with IBD
- Discuss the importance of administering guideline-concordant immunization to IBD patients
- Recognize the team needed to implement strategies to improve preventive care in IBD patients within a practice and health system
- Implement interventions that will coordinate care within their own practice and with PCPs to ensure appropriate vaccination
- Regularly review key quality measures for preventive care in patients with IBD
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Dr. Rubin discloses that he has consulted for Abbvie, Abgenomics, Allergan, Inc., Amgen, Celgene Corporation, Forward Pharma, Genentech/Roche, Janssen Pharmaceuticals, Merck & Co., Inc., Miraca Life Sciences, Mitsubishi Tanabe Pharma Development America, Inc., Napo Pharmaceuticals, Pfizer Inc., Salix Pharmaceuticals, Inc., Samsung Bioepis, Sandoz Pharmaceuticals, Shire, Takeda, and Target PharmaSolutions, Inc.; and received grant support from AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, Takeda, and UCB Pharma.
Dr. Melmed discloses that he has consulted for AbbVie, Celgene, Janssen Pharmaceuticals, Medtronic, Merck, Pfizer Inc., RedHill Biopharma, Samsung Bioepis, and Takeda.
Ms. Rubin has nothing to disclose.
Mahira Zec Bonomo, University of Chicago, Director for CME, has nothing to disclose.
Joshua Kilbridge, medical writer, has nothing to disclose.
Kathleen Hines, MCM Education VP, Editorial Services, has nothing to disclose.
Terry Ann Glauser, MD, MPH, MCM Education VP, Medical Affairs, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and MCM Education in collaboration with RealCME. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other health care professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME, please consult your professional licensing board.
Commercial Support Statements
This activity is supported by independent educational grants from Pfizer Inc. and Merck.
© 2018 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago Pritzker School of Medicine, Pfizer Inc, or Merck. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.